Tatva Chintan Pharma Chem Limited is a manufacturer of a diverse portfolio of structure Directing Agents, Phase Transfer Catalysts, electrolyte salts for batteries, and Pharmaceutical and Agrochemical Intermediates, and other Speciality chemicals.
WHY IT MIGHT GIVE A GOOD MOVE NOW:
Tatva's IPO's QIB was oversubscribed by 185.23 times. Meaning, institutions that planned to buy 50,000 shares got only 269 shares in the allotment. After the IPO Listing, the price dropped by 20.62% obviously due to listing gains enjoyed by retailers. For 11 weeks the share price formed a base and gave good time for big hands to accumulate. On the 12th week the price broke out of the IPO Listing price with huge volumes (the day before & the day after also) Out of 5.29 lac shares traded that day, 3.23 lac were traded in the last 30 minutes. This confirms my hypothesis of the Entry of big hands during the breakout. The price then tested 2 times the IPO listing high and took good support on it.
Tatva's Q2 results also dropped on 22nd October (before 3 big volume days) and the Q2 numbers beat both QoQ & YoY numbers which might be the trigger.
Key Points of the Company
Leading Chemical Manufacturer
Tatva Chintan operates in the space of niche specialty chemicals and is a globally recognized specialty chemical player with several market-leading products in its portfolio. The co. is the largest and only commercial manufacturer of structure-directing agents for zeolites in India (second globally) and caters to a wide range of industries across the globe.
Product portfolio: The company has manufactured over 154 products which can be divided into the following four broad categories
Structure Directing Agents(40% of the revenue) The Company’s SDAs are quarternary salts which are chemicals used in the Zeolite application. Zeolites have varied applications it is promoted with transition metals such as copper and iron to be active for selective catalytic reduction.
Phase Transfer Catalysts (27% of the revenue) PTC’s are widely used in green chemistry applications and are used for a variety of industrial processes. Phase transfer catalysts are a type of catalyst that allows a reactant to be migrated from one phase to another.
Electrolyte salts for supercapacitor batteries (1% of the revenue) The Company’s electrolyte salts are used in the manufacture of supercapacitor batteries, which are used in automobile batteries and other batteries. The Company is the largest producer of electrolyte salts for supercapacitor batteries in India.
Pharmaceutical, agrochemicals, and other specialty chemicals (30% of the revenue) The products manufactured by the company under this category are used in the manufacture of various pharmaceutical and agrochemical products as intermediates, disinfectants, and catalysts, and solvents. In addition, the company also manufacture specialty chemicals under this category that are used in dyes and pigments, personal care ingredients, flavor, and fragrance sectors
The Company has 47 products under their SDA product portfolio, 48 products under the PTC product portfolio, 6 products under the electrolyte salts for supercapacitor batteries portfolio, and 53 products under their PASC portfolio.
Manufacturing facilities
The Company operates through two manufacturing facilities situated at Ankleshwar and Dahej in Gujarat, both of which are strategically located very close to the Hazira port. These manufacturing facilities have an annual installed reactor capacity of 280 KL and 17 Assembly Lines.
Exports-driven
The company derives a majority of its revenue through exports (71% of the revenue) with Germany, the U.S., and China together accounting for 54.20%. Its top 10 customers constitute 60% of revenue.
Clientele List
The customers of the Company include Merck, Bayer AG, Asian Paints Ltd., Ipox Chemicals KFT, Laurus Labs Ltd, Tosoh Asia Pte. Ltd., SRF Limited, Navin Fluorine International Limited, Oriental Aromatics Ltd., Atul Limited and many others.
R&D Infrastructure
The company has a dedicated R&D facility, recognized by the DISR at Vadodara, Gujarat. The company has developed 53 products in the last three years which contributed 6.5 Crs revenue for the company.
Successful listing
The company got listed on the secondary exchanges on July 29 2021 with a 114% premium from its issue price. The 500 Crs issue got subscribed 180 times and became the most over subscriber IPO of 2021. The issue constituted of 275 Crs Offer for sale by the promoters and a fresh issue of 225 Crs.
Growth Strategies:
Expanding the Manufacturing Capabilities:
The Company has consistently grown its manufacturing and production capabilities. The Company’s aggregate manufacturing capacity has increased at a CAGR of 20.59% from an aggregate reactor capacity of 82 KL and zero Assembly Lines in FY2010 to 280 KL Reactor Capacity and 17 Assembly Lines as of FY21. The company will expand its Dahej Manufacturing facility and upgrade its R&D Infra with a CAPEx to the tune of 170 Crs.
Expand the existing product portfolio
The Company plans to continue to increase offerings in their current business segments as well as diversify into new products by tapping into segments which in the view of the company’s management have attractive growth prospects.
WHY IT MIGHT GIVE A GOOD MOVE NOW:
Tatva's IPO's QIB was oversubscribed by 185.23 times. Meaning, institutions that planned to buy 50,000 shares got only 269 shares in the allotment. After the IPO Listing, the price dropped by 20.62% obviously due to listing gains enjoyed by retailers. For 11 weeks the share price formed a base and gave good time for big hands to accumulate. On the 12th week the price broke out of the IPO Listing price with huge volumes (the day before & the day after also) Out of 5.29 lac shares traded that day, 3.23 lac were traded in the last 30 minutes. This confirms my hypothesis of the Entry of big hands during the breakout. The price then tested 2 times the IPO listing high and took good support on it.
Tatva's Q2 results also dropped on 22nd October (before 3 big volume days) and the Q2 numbers beat both QoQ & YoY numbers which might be the trigger.
Key Points of the Company
Leading Chemical Manufacturer
Tatva Chintan operates in the space of niche specialty chemicals and is a globally recognized specialty chemical player with several market-leading products in its portfolio. The co. is the largest and only commercial manufacturer of structure-directing agents for zeolites in India (second globally) and caters to a wide range of industries across the globe.
Product portfolio: The company has manufactured over 154 products which can be divided into the following four broad categories
Structure Directing Agents(40% of the revenue) The Company’s SDAs are quarternary salts which are chemicals used in the Zeolite application. Zeolites have varied applications it is promoted with transition metals such as copper and iron to be active for selective catalytic reduction.
Phase Transfer Catalysts (27% of the revenue) PTC’s are widely used in green chemistry applications and are used for a variety of industrial processes. Phase transfer catalysts are a type of catalyst that allows a reactant to be migrated from one phase to another.
Electrolyte salts for supercapacitor batteries (1% of the revenue) The Company’s electrolyte salts are used in the manufacture of supercapacitor batteries, which are used in automobile batteries and other batteries. The Company is the largest producer of electrolyte salts for supercapacitor batteries in India.
Pharmaceutical, agrochemicals, and other specialty chemicals (30% of the revenue) The products manufactured by the company under this category are used in the manufacture of various pharmaceutical and agrochemical products as intermediates, disinfectants, and catalysts, and solvents. In addition, the company also manufacture specialty chemicals under this category that are used in dyes and pigments, personal care ingredients, flavor, and fragrance sectors
The Company has 47 products under their SDA product portfolio, 48 products under the PTC product portfolio, 6 products under the electrolyte salts for supercapacitor batteries portfolio, and 53 products under their PASC portfolio.
Manufacturing facilities
The Company operates through two manufacturing facilities situated at Ankleshwar and Dahej in Gujarat, both of which are strategically located very close to the Hazira port. These manufacturing facilities have an annual installed reactor capacity of 280 KL and 17 Assembly Lines.
Exports-driven
The company derives a majority of its revenue through exports (71% of the revenue) with Germany, the U.S., and China together accounting for 54.20%. Its top 10 customers constitute 60% of revenue.
Clientele List
The customers of the Company include Merck, Bayer AG, Asian Paints Ltd., Ipox Chemicals KFT, Laurus Labs Ltd, Tosoh Asia Pte. Ltd., SRF Limited, Navin Fluorine International Limited, Oriental Aromatics Ltd., Atul Limited and many others.
R&D Infrastructure
The company has a dedicated R&D facility, recognized by the DISR at Vadodara, Gujarat. The company has developed 53 products in the last three years which contributed 6.5 Crs revenue for the company.
Successful listing
The company got listed on the secondary exchanges on July 29 2021 with a 114% premium from its issue price. The 500 Crs issue got subscribed 180 times and became the most over subscriber IPO of 2021. The issue constituted of 275 Crs Offer for sale by the promoters and a fresh issue of 225 Crs.
Growth Strategies:
Expanding the Manufacturing Capabilities:
The Company has consistently grown its manufacturing and production capabilities. The Company’s aggregate manufacturing capacity has increased at a CAGR of 20.59% from an aggregate reactor capacity of 82 KL and zero Assembly Lines in FY2010 to 280 KL Reactor Capacity and 17 Assembly Lines as of FY21. The company will expand its Dahej Manufacturing facility and upgrade its R&D Infra with a CAPEx to the tune of 170 Crs.
Expand the existing product portfolio
The Company plans to continue to increase offerings in their current business segments as well as diversify into new products by tapping into segments which in the view of the company’s management have attractive growth prospects.